Mechanisms and Antitumor Activity of a Binary EGFR/DNA-Targeting Strategy Overcomes Resistance of Glioblastoma Stem Cells to Temozolomide.
Zeinab SharifiBassam AbdulkarimBrian MeehanJanusz RakPaul DanielJulie SchmittNidia LauzonKolja EppertHeather M DuncanKevin PetreccaMarie-Christine GuiotBertrand Jean-ClaudeSiham SabriPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
These findings provide the molecular basis of binary EGFR/DNA targeting and uncover the oral bioavailability, blood-brain barrier permeability, and antitumor activity of ZR2002 supporting potential evaluation of this first-in-class drug in recurrent GBM.
Keyphrases
- blood brain barrier
- stem cells
- small cell lung cancer
- circulating tumor
- epidermal growth factor receptor
- tyrosine kinase
- cell free
- single molecule
- cancer therapy
- ionic liquid
- cerebral ischemia
- nucleic acid
- endothelial cells
- emergency department
- adverse drug
- risk assessment
- mesenchymal stem cells
- circulating tumor cells
- pet imaging
- brain injury
- drug induced